Intravitreal brolucizumab as treatment of early onset radiation retinopathy secondary to plaque brachytherapy for choroidal melanoma

PURPOSE: To describe the efficacy and safety of brolucizumab (Beovu®, Novartis Pharmaceuticals) in a case of cystoid macular edema associated with radiation retinopathy as a result of iodine-125 plaque brachytherapy (PBT) for choroidal melanoma, resistant to treatment with other anti-vascular endoth...

Descripción completa

Detalles Bibliográficos
Autores principales: Villegas, Natacha C., Mishra, Kapil, Steinle, Nathan, Liu, Wu, Beadle, Beth, Mruthyunjaya, Prithvi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9121253/
https://www.ncbi.nlm.nih.gov/pubmed/35599950
http://dx.doi.org/10.1016/j.ajoc.2022.101581

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9121253/
https://www.ncbi.nlm.nih.gov/pubmed/35599950
http://dx.doi.org/10.1016/j.ajoc.2022.101581

Ejemplares similares